Literature DB >> 21183068

Duchenne muscular dystrophy models show their age.

Jeffrey S Chamberlain1.   

Abstract

The lack of appropriate animal models has hampered efforts to develop therapies for Duchenne muscular dystrophy (DMD). A new mouse model lacking both dystrophin and telomerase (Sacco et al., 2010) closely mimics the pathological progression of human DMD and shows that muscle stem cell activity is a key determinant of disease severity.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Year:  2010        PMID： 21183068      PMCID： PMC3038548          DOI： 10.1016/j.cell.2010.12.005

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  9 in total

1.  Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche.

Authors:  Charlotte A Collins; Irwin Olsen; Peter S Zammit; Louise Heslop; Aviva Petrie; Terence A Partridge; Jennifer E Morgan
Journal:  Cell       Date:  2005-07-29       Impact factor: 41.582

2.  Longevity, stress response, and cancer in aging telomerase-deficient mice.

Authors:  K L Rudolph; S Chang; H W Lee; M Blasco; G J Gottlieb; C Greider; R A DePinho
Journal:  Cell       Date:  1999-03-05       Impact factor: 41.582

3.  Hypervariable ultra-long telomeres in mice.

Authors:  D Kipling; H J Cooke
Journal:  Nature       Date:  1990-09-27       Impact factor: 49.962

4.  Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

Authors:  Kazutoshi Takahashi; Shinya Yamanaka
Journal:  Cell       Date:  2006-08-10       Impact factor: 41.582

5.  Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy.

Authors:  A E Deconinck; J A Rafael; J A Skinner; S C Brown; A C Potter; L Metzinger; D J Watt; J G Dickson; J M Tinsley; K E Davies
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

6.  Telomere shortening and tumor formation by mouse cells lacking telomerase RNA.

Authors:  M A Blasco; H W Lee; M P Hande; E Samper; P M Lansdorp; R A DePinho; C W Greider
Journal:  Cell       Date:  1997-10-03       Impact factor: 41.582

7.  A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy.

Authors:  Kumaran Chandrasekharan; Jung Hae Yoon; Ying Xu; Sarah deVries; Marybeth Camboni; Paulus M L Janssen; Ajit Varki; Paul T Martin
Journal:  Sci Transl Med       Date:  2010-07-28       Impact factor: 17.956

8.  Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma.

Authors:  Jeffrey S Chamberlain; Joseph Metzger; Morayma Reyes; DeWayne Townsend; John A Faulkner
Journal:  FASEB J       Date:  2007-03-14       Impact factor: 5.191

Review 9.  Emerging strategies for cell and gene therapy of the muscular dystrophies.

Authors:  Lindsey A Muir; Jeffrey S Chamberlain
Journal:  Expert Rev Mol Med       Date:  2009-06-25       Impact factor: 5.600
  9 in total
  10 in total

Review 1.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

Review 2.  Animal models of human genetic diseases: do they need to be faithful to be useful?

Authors:  Jean-Louis Guénet
Journal:  Mol Genet Genomics       Date:  2011-05-06       Impact factor: 3.291

3.  Expression of the dystrophin isoform Dp116 preserves functional muscle mass and extends lifespan without preventing dystrophy in severely dystrophic mice.

Authors:  Luke M Judge; Andrea L H Arnett; Glen B Banks; Jeffrey S Chamberlain
Journal:  Hum Mol Genet       Date:  2011-09-23       Impact factor: 6.150

4.  Reduced IGF signaling prevents muscle cell death in a Caenorhabditis elegans model of muscular dystrophy.

Authors:  Kelly Hyunju Oh; Hongkyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

Review 5.  Immune-mediated pathology in Duchenne muscular dystrophy.

Authors:  Amy S Rosenberg; Montserrat Puig; Kanneboyina Nagaraju; Eric P Hoffman; S Armando Villalta; V Ashutosh Rao; Lalage M Wakefield; Janet Woodcock
Journal:  Sci Transl Med       Date:  2015-08-05       Impact factor: 17.956

6.  Crosstalk between RyR2 oxidation and phosphorylation contributes to cardiac dysfunction in mice with Duchenne muscular dystrophy.

Authors:  Qiongling Wang; Wei Wang; Guoliang Wang; George G Rodney; Xander H T Wehrens
Journal:  J Mol Cell Cardiol       Date:  2015-11-07       Impact factor: 5.000

7.  Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy.

Authors:  Foteini Mourkioti; Jackie Kustan; Peggy Kraft; John W Day; Ming-Ming Zhao; Maria Kost-Alimova; Alexei Protopopov; Ronald A DePinho; Daniel Bernstein; Alan K Meeker; Helen M Blau
Journal:  Nat Cell Biol       Date:  2013-07-07       Impact factor: 28.824

8.  Skeletal muscle characterization of Japanese quail line selectively bred for lower body weight as an avian model of delayed muscle growth with hypoplasia.

Authors:  Young Min Choi; Yeunsu Suh; Sangsu Shin; Kichoon Lee
Journal:  PLoS One       Date:  2014-04-24       Impact factor: 3.240

Review 9.  Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders.

Authors:  Rosamund C Smith; Boris K Lin
Journal:  Curr Opin Support Palliat Care       Date:  2013-12       Impact factor: 2.302

10.  Perturbation of PI3K/Akt signaling affected autophagy modulation in dystrophin-deficient myoblasts.

Authors:  Muhammad Dain Yazid; Chen Hung-Chih
Journal:  Cell Commun Signal       Date:  2021-10-27       Impact factor: 5.712
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.